Skip to main content
SpringerLink
Log in

Usefulness of Serum Anti-p53 Antibody Measurement in Patients Undergoing Hepatectomy for Colorectal Liver Metastases

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

While anti-p53 antibody (p53-Ab) is a potential marker for early detection of colorectal cancer, its clinical utility in patients with advanced colorectal cancer remains unknown.

Methods

The clinical significance of p53-Ab was investigated by analyzing the data of 206 patients who underwent curative resection for colorectal liver metastases.

Results

Of the 206 patients, 60 (29%) were seropositive and 146 were seronegative for p53-Ab before the surgery. The preoperative serum p53-Ab level showed no significant correlation with the serum CEA or serum CA19-9 levels. The perioperative changes in serum p53-Ab positivity were significantly correlated with the preoperative serum p53-Ab levels and multivariate analysis confirmed that a higher preoperative p53-Ab level was independently associated with a worse recurrence-free survival (hazard ratio [HR], 1.07; 95% CI, 1.01–1.13; P = 0.033 per + 100 U/mL), even after adjustments for other oncological factors, including the preoperative serum CEA level.

Conclusion

Higher preoperative p53-Ab levels were associated with a higher risk of recurrence after curative resection of colorectal liver metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22):3677–3683

    PubMed  PubMed Central  Google Scholar 

  2. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F et al (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17(10):1225–1239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH (2009) Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 16(11):3087–3093

    Article  PubMed  Google Scholar 

  4. Bhatti I, Patel M, Dennison AR, Thomas MW, Garcea G (2015) Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer. Int J Surg 16(Pt A):123–128

    Article  PubMed  Google Scholar 

  5. Hammel P, Leroy-Viard K, Chaumette MT, Villaudy J, Falzone MC, Rouillard D et al (1999) Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer 81(5):712–718

    Article  CAS  PubMed  Google Scholar 

  6. Liu S, Tan Q, Song Y, Shi Y, Han X (2020) Anti-p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: a meta-analysis. Scand J Immunol 91(2):e12829

    PubMed  Google Scholar 

  7. Suppiah A, Greenman J (2013) Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. World J Gastroenterol 19(29):4651–4670

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kressner U, Glimelius B, Bergstrom R, Pahlman L, Larsson A, Lindmark G (1998) Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 77(11):1848–1851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yamaguchi T, Takii Y, Maruyama S (2014) Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients. Surg Today 44(8):1529–1535

    Article  CAS  PubMed  Google Scholar 

  10. Shindoh J, Nishioka Y, Yoshioka R, Sugawara T, Sakamoto Y, Hasegawa K et al (2016) KRAS mutation status predicts site-specific recurrence and survival after resection of colorectal liver metastases irrespective of location of the primary lesion. Ann Surg Oncol 23(6):1890–1896

    Article  PubMed  Google Scholar 

  11. Suzuki T, Shimada H, Ushigome M, Koike J, Funahashi K, Nemoto T et al (2016) Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin J Gastroenterol 9(2):55–58

    Article  PubMed  Google Scholar 

  12. Abe S, Kawai K, Ishihara S, Nozawa H, Hata K, Kiyomatsu T et al (2017) Prognostic value of pre- and postoperative anti-p53 antibody levels in colorectal cancer patients: a retrospective study. Oncology 92(1):31–38

    Article  CAS  PubMed  Google Scholar 

  13. Tang R, Yeh CY, Wang JY, Changchien CR, Chen JS, Hsieh LL (2009) Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol 16(9):2516–2523

    Article  PubMed  Google Scholar 

  14. Chang SC, Lin JK, Lin TC, Liang WY (2005) Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol 26(1):65–75

    CAS  PubMed  Google Scholar 

  15. Shiota G, Ishida M, Noguchi N, Oyama K, Takano Y, Okubo M et al (2000) Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci 45(1):122–128

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by study grant from Okinaka Memorial Institute for Medical Disease.

Author information

Author notes

  1. Kazutaka Kojima and Junichi Shindoh equally contributed to this work

Authors and Affiliations

  1. Hepatobiliary-Pancreatic Surgery Division, Department of Gastroenterological Surgery, Toranomon Hospital, 2-2-2 Toranomon, Minatoku, Tokyo, 105-8470, Japan

    Kazutaka Kojima, Junichi Shindoh, Miho Akabane, Ryosuke Umino, Yuta Kobayashi, Satoshi Okubo & Masaji Hashimoto

  2. Okinaka Memorial Institute for Medical Diseases, Toranomon, Japan

    Junichi Shindoh

Authors
  1. Kazutaka Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junichi Shindoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miho Akabane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryosuke Umino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuta Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Satoshi Okubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masaji Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Junichi Shindoh.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 26 kb)

Supplemental Figure 1. Study population (PPTX 36 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kojima, K., Shindoh, J., Akabane, M. et al. Usefulness of Serum Anti-p53 Antibody Measurement in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. World J Surg 45, 1906–1912 (2021). https://doi.org/10.1007/s00268-021-06049-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-021-06049-9

Search

Navigation